CMPS vs. MESO, ADPT, VERA, DYN, GPCR, ANIP, SPRY, CALT, ETNB, and OCUL
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
Mesoblast (NASDAQ:MESO) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
Mesoblast presently has a consensus target price of $18.00, indicating a potential upside of 62.82%. COMPASS Pathways has a consensus target price of $20.20, indicating a potential upside of 386.16%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than Mesoblast.
Mesoblast's return on equity of 0.00% beat COMPASS Pathways' return on equity.
Mesoblast received 346 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 81.93% of users gave COMPASS Pathways an outperform vote while only 70.41% of users gave Mesoblast an outperform vote.
1.4% of Mesoblast shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Mesoblast has higher revenue and earnings than COMPASS Pathways.
In the previous week, COMPASS Pathways had 4 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for COMPASS Pathways and 6 mentions for Mesoblast. COMPASS Pathways' average media sentiment score of 1.24 beat Mesoblast's score of 0.50 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Mesoblast has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.
Summary
Mesoblast and COMPASS Pathways tied by winning 7 of the 14 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 5/21/2025 by MarketBeat.com Staff
